Tel: 01274 236873 | info@arterius.co.uk

PRODUCTS

PRODUCTS

Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES); come in a range of sizes and lengths; Provide equivalent mechanical performance (radial strength) to the best-in-class DES products.
Read More…

ABOUT

ABOUT

Founded in 2009, Bradford-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile.
The founding directors have significant experience in the development of medical devices and in the cardiovascular devices field in particular. Read More…

WHAT WE DO

WHAT WE DO

Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent with a market leading profile. Read More…

Latest News

Biomedical Catalyst Grant Award to Arterius Limited

Biomedical Catalyst Grant Award to Arterius Limited

Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb™.

ArterioSorb™ is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). CAD is the leading cause of death both in the UK and worldwide, responsible for more than 73,000 deaths in the UK each year. ArterioSorb™ is a next-generation bioresorbable cardiovascular scaffold (BRS, stent), to be implanted within the coronary arteries in order to open blocked vessels, and to biodegrade within two years when healing is complete and it is no longer needed. In this 24-month project, Arterius will perform the in-vitro and in-vivo studies necessary to demonstrate the safety and efficacy of ArterioSorb™. After completion of this study, the company will enter the First-in-Man trials and commercialisation, which will enhance the growth and global profile of the company, create new skilled jobs and enhance our global competitiveness in the field of stent technologies. There is currently no UK company offering a BRS for the global market. Following this project, ArterioSorb™ will launch to compete with the global BRS products. The goal of Arterius is to develop as a major UK SME with global competitiveness in the polymer based BRS market to treat cardiovascular disease.

Dr Kadem Al-Lamee, CEO, said “Development funding supported by the Innovate UK (TSB) programme will significantly help the company to stay ahead of the competition and to continue their ongoing collaboration with the UK academics and clinicians, in order to continue this ground-breaking research and to commence clinical trials by 2019”.

END

The Innovate UK (TSB) is the UK’s innovation agency.  Its goal is to accelerate economic growth by stimulating and supporting business-led innovation.  Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

The Biomedical Catalyst programme is managed by the Innovate UK (TSB), It offers funding to small and medium-sized enterprises (SMEs) with potential and ambition for growth, to engage in game changing, cutting edge innovation R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge.

http://www.innovateuk.org/deliveringinnovation/smart.ashx